Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexza Pharmaceuticals Inc And Grupo Ferrer Internacional, S.A. Receives Marketing Authorization For ADASUVE In European Union


Thursday, 21 Feb 2013 09:02am EST 

Alexza Pharmaceuticals Inc and Grupo Ferrer Internacional, S.A., announced that the European Commission has granted marketing authorization for ADASUVE (Staccato loxapine). In the European Union (EU), ADASUVE, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The ADASUVE marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that ADASUVE is administered only in a hospital setting under the supervision of a healthcare professional. 

Company Quote

2.54
-0.16 -5.93%
4:00pm EDT